{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:52:14Z","timestamp":1773312734191,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.pcad.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T01:44:36Z","timestamp":1691977476000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Art and science of risk stratification of sudden cardiac death in hypertrophic cardiomyopathy: Current state, unknowns, and future directions"],"prefix":"10.1016","volume":"80","author":[{"given":"Konstantinos C.","family":"Siontis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve R.","family":"Ommen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Geske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2023.08.005_bb0005","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","article-title":"Hypertrophic cardiomyopathy: clinical update","volume":"6","author":"Geske","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pcad.2023.08.005_bb0010","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the sarcomeric human cardiomyopathy registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0015","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","article-title":"Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies","volume":"65","author":"Maron","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamacardio.2019.4534","article-title":"Mortality among referral patients with hypertrophic cardiomyopathy vs the general European population","volume":"5","author":"Lorenzini","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0025","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jacc.2022.02.032","article-title":"Survival following alcohol septal ablation or septal Myectomy for patients with obstructive hypertrophic cardiomyopathy","volume":"79","author":"Cui","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0030","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/CIRCEP.113.001376","article-title":"Pathogeneses of sudden cardiac death in national collegiate athletic association athletes","volume":"7","author":"Harmon","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0035","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"35","key":"10.1016\/j.pcad.2023.08.005_bb0040","first-page":"2733","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"2014","author":"Authors\/Task Forcem","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0045","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1016\/j.jacc.2011.10.825","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"58","author":"Gersh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0050","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jce.13194","article-title":"Ventricular Tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications","volume":"28","author":"Link","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0055","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1111\/jce.15231","article-title":"Purkinje triggers of ventricular fibrillation in patients with hypertrophic cardiomyopathy","volume":"32","author":"Hocini","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0060","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJM200002103420601","article-title":"Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy","volume":"342","author":"Maron","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.08.005_bb0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCRESAHA.119.315159","article-title":"Paradigm of sudden death prevention in hypertrophic cardiomyopathy","volume":"125","author":"Maron","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2023.08.005_bb0070","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","author":"O\u2019Mahony","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0075","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/CIRCULATIONAHA.117.030437","article-title":"International external validation study of the 2014 European Society of Cardiology Guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM)","volume":"137","author":"O\u2019Mahony","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0080","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/heartjnl-2018-313700","article-title":"Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"105","author":"O\u2019Mahony","year":"2019","journal-title":"Heart."},{"key":"10.1016\/j.pcad.2023.08.005_bb0085","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1001\/jamacardio.2019.1391","article-title":"Enhanced American College of Cardiology\/American Heart Association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy","volume":"4","author":"Maron","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0090","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1136\/heartjnl-2019-315160","article-title":"Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians","volume":"105","author":"Choi","year":"2019","journal-title":"Heart."},{"key":"10.1016\/j.pcad.2023.08.005_bb0095","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCEP.114.002553","article-title":"Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Vriesendorp","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0100","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jacep.2022.07.012","article-title":"Temporal and global trends of the incidence of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Abdelfattah","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0105","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1093\/eurheartj\/ehab598","article-title":"Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy","volume":"42","author":"Nauffal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0110","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.athoracsur.2019.03.026","article-title":"Survival after Myectomy for obstructive hypertrophic cardiomyopathy: what causes late mortality?","volume":"108","author":"Nguyen","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"750\u2013759","key":"10.1016\/j.pcad.2023.08.005_bb0115","article-title":"Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy: potential for refinement of current criteria","volume":"156","author":"Desai","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2023.08.005_bb0120","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0125","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0130","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.pcad.2023.08.005_bb0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of Aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0140","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0150","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","article-title":"Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international Sarcomeric human cardiomyopathy registry","volume":"13","author":"Canepa","year":"2020","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2023.08.005_bb0155","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018527","article-title":"Characteristics and outcomes of elderly patients with hypertrophic cardiomyopathy","volume":"10","author":"Alashi","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2023.08.005_bb0160","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.008123","article-title":"Long-term outcome in high-risk patients with hypertrophic cardiomyopathy after primary prevention defibrillator implants","volume":"13","author":"Rowin","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0165","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacep.2019.05.026","article-title":"Cardiovascular implantable electronic device infection: procedure versus lifetime risk","volume":"5","author":"Tarakji","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCEP.113.001217","article-title":"Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis","volume":"7","author":"Tan","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0175","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1093\/eurheartj\/ehac496","article-title":"Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial","volume":"43","author":"Knops","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.048728","article-title":"Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial","volume":"143","author":"Gold","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0185","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2206485","article-title":"Efficacy and safety of an extravascular implantable cardioverter-defibrillator","volume":"387","author":"Friedman","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.08.005_bb0190","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.hrthm.2016.01.001","article-title":"Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts","volume":"13","author":"Lambiase","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2023.08.005_bb0195","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jacep.2020.03.015","article-title":"Evidence that subcutaneous implantable cardioverter-defibrillators are effective and reliable in hypertrophic cardiomyopathy","volume":"6","author":"Maron","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0200","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.hrthm.2020.02.008","article-title":"Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: an international multicenter study","volume":"17","author":"Nazer","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.pcad.2023.08.005_bb0205","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1161\/CIRCEP.111.962043","article-title":"Sudden cardiac death in hypertrophic cardiomyopathy","volume":"6","author":"O\u2019Mahony","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0210","first-page":"10","article-title":"Prognostic implications of nonsustained ventricular tachycardia in high-risk patients with hypertrophic cardiomyopathy","author":"Wang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0215","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0735-1097(03)00827-1","article-title":"Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients","volume":"42","author":"Monserrat","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1161\/CIRCULATIONAHA.120.047235","article-title":"A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy","volume":"142","author":"Miron","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0225","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1056\/NEJMp0707996","article-title":"The vanishing nonforensic autopsy","volume":"358","author":"Shojania","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2023.08.005_bb0230","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/eurheartj\/ehr092","article-title":"Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy","volume":"32","author":"Christiaans","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0235","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0240","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacc.2018.05.060","article-title":"Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function","volume":"72","author":"Mentias","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0245","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/CIRCULATIONAHA.108.798314","article-title":"Syncope and risk of sudden death in hypertrophic cardiomyopathy","volume":"119","author":"Spirito","year":"2009","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0250","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ijcard.2022.10.153","article-title":"Syncope in hypertrophic cardiomyopathy (part II): an expert consensus statement on the diagnosis and management","volume":"370","author":"Brignole","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0255","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2016.11.063","article-title":"Hypertrophic cardiomyopathy with left ventricular apical aneurysm: implications for risk stratification and management","volume":"69","author":"Rowin","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0260","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1161\/CIRCULATIONAHA.108.781401","article-title":"Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy","volume":"118","author":"Maron","year":"2008","journal-title":"Circulation."},{"key":"10.1016\/j.pcad.2023.08.005_bb0265","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.echo.2021.07.015","article-title":"Left ventricular apical aneurysms in hypertrophic cardiomyopathy: equivalent detection by magnetic resonance imaging and contrast echocardiography","volume":"34","author":"Lee","year":"2021","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.pcad.2023.08.005_bb0270","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10554-013-0355-y","article-title":"Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI","volume":"30","author":"Kebed","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2023.08.005_bb0275","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","article-title":"Women with hypertrophic cardiomyopathy have worse survival","volume":"38","author":"Geske","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2023.08.005_bb0280","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012041","article-title":"Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy","volume":"8","author":"Rowin","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pcad.2023.08.005_bb0285","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1161\/CIRCIMAGING.112.976738","article-title":"Myocardial tissue characterization using magnetic resonance noncontrast t1 mapping in hypertrophic and dilated cardiomyopathy","volume":"5","author":"Dass","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2023.08.005_bb0290","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1007\/s00330-017-4869-x","article-title":"Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR","volume":"27","author":"Avanesov","year":"2017","journal-title":"Eur Radiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0295","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1007\/s00330-020-07650-7","article-title":"Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy","volume":"31","author":"Li","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0300","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.jacc.2019.02.065","article-title":"Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias","volume":"73","author":"Ariga","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10554-017-1252-6","article-title":"High T2-weighted signal intensity for risk prediction of sudden cardiac death in hypertrophic cardiomyopathy","volume":"34","author":"Gommans","year":"2018","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2023.08.005_bb0310","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jcmg.2018.07.016","article-title":"Prognostic value of global longitudinal strain in hypertrophic cardiomyopathy: a systematic review of existing literature","volume":"12","author":"Tower-Rader","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.pcad.2023.08.005_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/jce.14792","article-title":"EvaLuation using cardiac Insertable devices and TelephonE in hypertrophic cardiomyopathy (ELUCIDATE HCM): a prospective observational study on incidence of arrhythmias","volume":"32","author":"Magnusson","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0320","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11936-018-0633-z","article-title":"Autonomic regulation and ventricular arrhythmias","volume":"20","author":"Meng","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.pcad.2023.08.005_bb0325","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2019.12.030","article-title":"Detection of hypertrophic cardiomyopathy using a convolutional neural network-enabled electrocardiogram","volume":"75","author":"Ko","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0330","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005289","article-title":"Automated and interpretable patient ECG profiles for disease detection, tracking, and discovery","volume":"12","author":"Tison","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.pcad.2023.08.005_bb0335","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jacc.2022.01.005","article-title":"Assessment of disease status and treatment response with artificial intelligence-enhanced electrocardiography in obstructive hypertrophic cardiomyopathy","volume":"79","author":"Tison","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2023.08.005_bb0340","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cvdhj.2021.05.005","article-title":"Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: a paradigm for longitudinal device follow-up","volume":"2","author":"Siontis","year":"2021","journal-title":"Cardiovasc Digit Health J"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062023000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:21:41Z","timestamp":1758500501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062023000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":68,"alternative-id":["S0033062023000804"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2023.08.005","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Art and science of risk stratification of sudden cardiac death in hypertrophic cardiomyopathy: Current state, unknowns, and future directions","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}